Analysis of the efficacy and safety of proton radiotherapy for primary hepatocellular carcinoma
10.3760/cma.j.cn121382-20221012-00206
- VernacularTitle:质子放射治疗原发性肝细胞癌的疗效、安全性及影响因素分析
- Author:
Gang QIAO
1
;
Lili ZHENG
;
Xi REN
;
Qing CHEN
;
Xiangkui MU
Author Information
1. 淄博万杰肿瘤医院，淄博 255213
- Keywords:
Proton radiation therapy;
Primary hepatocellular carcinoma;
Survival rate;
Local control rate
- From:
International Journal of Biomedical Engineering
2023;46(2):128-131
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the efficacy, safety and prognostic factors affecting survival of proton radiation therapy for primary hepatocellular carcinoma (HCC).Methods:Forty-four patients with primary hepatocellular carcinoma treated at Zibo Wanjie Cancer Hospital in Shandong Province from June 15, 2005 to September 12, 2018 were enrolled and given proton radiation therapy with a single dose of 2-5 Gy and a total dose of 25-75 Gy. The overall and local control rates, factors influencing survival, and adverse effects were observed during a follow-up period of 12 to 120 months.Results:The overall survival rates of all patients were 79.5% at 1 year, 68.2% at 2 years, 50.0% at 3 years, and 45.5% at 5 years. The overall local control rate was 95.5%. Patients older than 50 years had a longer overall survival (Log Rank Chi-Square of 4.787, P = 0.029). Child-Pugh A classification had better overall survival compared with B classification (Log Rank Chi-Square 4.077, P = 0.043). The main adverse reactions were skin reactions and gastrointestinal reactions. Among the patients with adverse reactions, 23 patients had skin reactions and 9 patients had mild gastrointestinal reactions, and no serious adverse events were found. Conclusions:Proton radiation therapy has good efficacy and high safety in patients with HCC. Age and Child-Pugh classification are prognostic factors affecting survival after proton radiation therapy.
